Lineage Cell Therapeutics Launches COR1 Cell Therapy Program to Address Global Corneal Transplant Shortage
Key Insights
Lineage Cell Therapeutics has launched COR1, a preclinical corneal endothelial cell therapy program targeting Fuchs endothelial corneal dystrophy (search) and bullous keratopathy (search) using its proprietary AlloSCOPE platform.
The program addresses a critical unmet need, as global demand for corneal transplants reaches 12.7 million cases annually while only one donor cornea is available for every 70 diseased eyes.
COR1 leverages manufacturing expertise from Lineage's OpRegen program and aims to provide a consistent, off-the-shelf allogeneic source of corneal endothelial cells (search) without relying on human organ donors.
Lineage Cell Therapeutics has announced the launch of COR1, a new corneal endothelial cell therapy program designed to address the global shortage of donor corneas for transplantation. The preclinical program targets corneal endothelial disease (search), specifically Fuchs endothelial corneal dystrophy (search) (FECD) and bullous keratopathy (search), utilizing the company's proprietary AlloSCOPE platform to manufacture "off-the-shelf" therapeutic cells.
Addressing Critical Unmet Medical Need
The global demand for corneal transplants significantly outweighs supply, with 12.7 million cases needed annually while only one donor cornea is available for every 70 diseased eyes worldwide. Over 13 million people are currently waiting for corneal transplants, highlighting the urgent need for alternative treatment approaches.
"Millions of people are candidates for corneal transplants for which today there is only one donor for every 70 diseased eyes globally," stated Brian M. Culley, Lineage CEO. "The current supply of CEnCs from cadaveric sources is further limited by the low availability of organ donors, as well as by inconsistent yield and quality."
Target Disease Population
Fuchs endothelial corneal dystrophy (search) represents the most common primary corneal endothelial dystrophy and the leading indication for corneal transplantation worldwide. The condition affects approximately 7.33% of adults over 30 years of age globally, with the patient population projected to rise from approximately 300 million in 2020 to 415 million by 2050. The disease is characterized by progressive decline of corneal endothelial cells (search) and formation of extracellular matrix excrescences in Descemet's membrane, leading to corneal edema and vision loss.
The current addressable market spans 2-6 million patients in the United States and approximately 16 million in Europe, with a predicted 10-year compound annual growth rate of 7.7%.
AlloSCOPE Platform Technology
COR1 is manufactured using Lineage's AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform, which can produce millions of doses of allogeneic, cell-based products derived from a single initial pluripotent cell line. The platform utilizes directed differentiation protocols to guide self-renewing pluripotent stem cells into specific functional cell types.
The company has successfully manufactured corneal endothelial cells (search) with identity, morphological, and functional characteristics that meet initial internal criteria and support further development. Culley noted that the company believes recent accomplishments with the AlloSCOPE "5D" manufacturing process could be applied to reduce production costs through large-scale production.
Clinical Precedent and Development Strategy
The program benefits from existing clinical precedent, as corneal endothelial cell therapy from cadaveric sources has already been approved in Japan to treat corneal endothelial disease (search). This regulatory approval provides evidence for the underlying mechanism of action and creates what Culley described as "a highly attractive opportunity for us to develop a more consistent and cost-effective product."
Cell therapy treatment for FECD is minimally invasive compared to corneal transplant surgery and is administered via injection into the anterior chamber of the eye. Following injection, patients remain supine for several hours to enable cells to settle onto the back surface of the cornea. If successful, the new endothelial cells form a monolayer and restore the cornea's fluid-pumping function, clearing corneal edema.
Leveraging OpRegen Expertise
The COR1 program incorporates development expertise from Lineage's OpRegen program, an investigational allogeneic retinal pigmented epithelial cell therapy currently in Phase 2a development for geographic atrophy (search) secondary to dry age-related macular degeneration (search). OpRegen is being developed through a global collaboration between Lineage, Roche, and Genentech.
The company reported Phase 1/2 data for OpRegen in April 2023, followed by 36-month findings in June 2025, demonstrating the potential for OpRegen-treated retinal pigment epithelial cells to benefit remaining retinal cells within atrophic areas.
Next Steps
Lineage plans to advance COR1 into preclinical testing, though the company has not yet shared specific timelines for clinical development advancement. The program represents a new internally-developed and wholly-owned asset that benefits from the company's existing ophthalmology and manufacturing expertise.